Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
45.2M
-
Number of holders
-
140
-
Total 13F shares, excl. options
-
57.3M
-
Shares change
-
+1.05M
-
Total reported value, excl. options
-
$1.2B
-
Value change
-
+$3.36M
-
Put/Call ratio
-
2.99
-
Number of buys
-
80
-
Number of sells
-
-66
-
Price
-
$20.99
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q2 2024
183 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 140 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57.3M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5.1M shares), BlackRock Inc. (4.9M shares), VR Adviser, LLC (4.4M shares), GOLDMAN SACHS GROUP INC (4.13M shares), Deep Track Capital, LP (4.06M shares), BVF INC/IL (3.92M shares), JANUS HENDERSON GROUP PLC (3.2M shares), VIKING GLOBAL INVESTORS LP (2.93M shares), VANGUARD GROUP INC (2.53M shares), and STATE STREET CORP (2.08M shares).
This table shows the top 140 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.